Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
P/B ratio for Pliant Therapeutics, Inc. (PLRX)
P/B ratio as of 2023: 2.25
According to Pliant Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.25. At the end of 2022 the company had a P/B ratio of 2.59.
P/B ratio history for Pliant Therapeutics, Inc. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.25 |
| 2022 | 2.59 |
| 2021 | 2.43 |
| 2020 | 2.85 |
| 2019 | -1740.79 |
| 2018 | -398.71 |
| 2017 | 5.12 |